Table 2.
Patient population and clinical scenario among included studies.
| Patient population | Study | Investigational drug |
|---|---|---|
| STEMI | APEX-MI [28] | Pexelizumab |
| COMMA [16] | ||
| COMPLY [16] | ||
| VCU-ART3 [34] | Anakinra | |
| NSTEMI | MRC-ILA Heart Study [35] | Anakinra |
| MI (STEMI and NSTEMI) | CANTOS [17] | Canakinumab |
| LATITUDE TIMI 60 [43] | Losmapimod | |
| COLCOT [37] | Colchicine | |
| ACS (STEMI, NSTEMI, or UA) | SOLID TIMI 52 [38] | Darapladib |
| FRANCIS [41] | Varespladib | |
| VISTA-16 [40] | Varespladib | |
| CABG | PRIMO CABG 1 [32] | Pexelizumab |
| PRIMO CABG 2 [31] | ||
| Pexelizumab Study Investigators [30] | ||
| SELECT-CABG [42] | Inclacumab | |
| Stable CAD | STABILITY [39] | Darapladib |
| LoDoCo [36] | Colchicine |
∗Study with subgroup analysis of its primary end points.